

**REPORT OF THE TRUSTEES AND  
UNAUDITED FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31ST MARCH 2024  
FOR  
LEUKAEMIA BUSTERS CIO**

Leukaemia Busters  
MP3, Southampton General Hospital  
Southampton  
Hampshire  
SO16 6YD

**LEUKAEMIA BUSTERS**  
**CONTENTS OF THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31ST MARCH 2024**

---

	<b>Page</b>
<b>Report of the Trustees</b>	1 to 5
<b>Independent Examiner's Report</b>	6
<b>Statement of Financial Activities</b>	7
<b>Balance Sheet</b>	8
<b>Notes to the Financial Statements</b>	9 to 14

---

**LEUKAEMIA BUSTERS**  
**REPORT OF THE TRUSTEES**  
**FOR THE YEAR ENDED 31ST MARCH 2024**

---

The trustees present their report with the financial statements of the charity for the year ended 31st March 2024. The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2015).

## **OBJECTIVES AND ACTIVITIES**

### **Objectives and aims**

Leukaemia Busters was established as a Charitable Incorporated Organisation (CIO) formed under a constitution dated 21st May 2014. The objectives of the charity are to relieve patients with leukaemia, lymphoma and other blood-related cancers through funding the pursuit of pure and translational scientific research aimed at the development of new improved therapies for these malignant diseases. The objective is achieved through research conducted in our dedicated research laboratory, The Simon Flavell Leukaemia Research Laboratory based at Southampton General Hospital. The charity's vision is a world in which leukaemia and related conditions are safely, quickly and completely cured and our mission is to fund and conduct research focused on providing antibody-based treatments that will provide this for leukaemia patients.

The Trustees have considered the Charity Commission's latest general guidance on public benefit when reviewing our aims and objectives and planning future activities and are satisfied that our main research activities meet requirements.

We pursue a research portfolio that has a translational value; that is research that is intended to yield practical benefits for patients through the development of novel treatments based on antibodies or other similar molecules. Unlike many medical research charities Leukaemia Busters raises funds for direct application by its own scientists in its own laboratory in Southampton, and for collaborations with major national and overseas institutions under the management of the charity's scientific directors. In this way we have been able to hold firm to on-going investment in promising lines of research that meet our core objectives without our research having to compete for grant awards from external bodies whilst still maintaining scientific excellence through exhaustive independent peer review of our publications and scientific work.

### **Research activities**

The charity's flagship laboratory, The Simon Flavell Leukaemia Research Laboratory has been continuously engaged in translational and clinical research since 1991. During this time Leukaemia Busters supported scientists have made landmark discoveries on antibody-based treatments for leukaemia and lymphoma, some of which are likely to have an important translational impact on the development of future treatments.

Over the years eight novel immunotoxin therapeutic molecules have been produced by our scientists and two of these (BU12-SAP and OKT10-SAP) have been investigated in early phase clinical trials in both adults and children. Leukaemia Busters working in collaboration with the United Kingdom Childhood Cancer Study Group and Cancer Research UK conducted the first early phase clinical trial in the UK with the Leukaemia Busters developed antibody-based drug, BU12-SAP in children with relapsed leukaemia. This landmark clinical study in children with, what were at the time incurable forms of leukaemia, opened the way for others to follow.

The past year has seen a continuation of experimental studies centred on investigating the mechanism(s) by which a class of molecule called triterpenoid saponins enhance the effectiveness of immunotoxin-based treatments at killing human leukaemia cells. Work in this area promises to contribute to increasing the efficiency and effectiveness of certain types of antibody therapy and understanding the mechanism behind this is of vital importance if such an approach is to be developed for safe and effective clinical use. However, our scientists have now had to cease work on this due to the enforced closure of The Simon Flavell Laboratory in December 2023.

Closure of our laboratory was due to circumstances beyond the charity's control as the School of Medicine, within Southampton General Hospital, revealed redevelopment plans that necessitated repossession of the space our laboratory occupied. The closure of our flagship laboratory that has been so successful over the years unfortunately resulted in redundancy for two of the charity's scientific staff and statutory redundancy payments were paid to both at termination of their contracts on the 15th December 2023. The loss of our research laboratory has forced us to explore other ways of supporting research in order to meet the stated objects of the charity. We are happy to say that the trustees have devised what they believe will be a highly effective way of achieving this in the future.

Recruiting and retaining the best scientific minds to conduct research work on the development of novel immunotherapies and making improvements to existing ones for leukaemia and other blood-related malignancies is of vital importance if continued progress is to be made for the benefit of future patients. The charity's trustees have therefore reached the decision to create a grant award scheme to support early career research scientists at accredited academic research institutions in Southampton and elsewhere in the UK. These competitive awards will be termed Leukaemia Busters Simon Flavell Research Fellowships

**LEUKAEMIA BUSTERS**  
**REPORT OF THE TRUSTEES**  
**FOR THE YEAR ENDED 31ST MARCH 2024**

---

and will be based on a defined research project of translational value for leukaemia patients as devised by the applicants. All submitted projects will be subject to rigorous peer review. Only those projects of the highest standard and of translational relevance for leukaemia patients will be supported. Such an early career fellowship scheme is designed to help nurture and retain talented young scientists immediately or soon after completion of their PhD qualification and will provide two years stipend support together with research expenses. Preparations to roll out this scheme are now well underway and we anticipate that the charity will be in a position to begin making fellowship awards sometime during 2025.

The creation of our early career research fellowship scheme is an exciting new development for the charity and will ensure that we will remain at the forefront of cutting-edge research and continue to contribute to the discovery and development of novel immunotherapies for the direct benefit of patients with haematological malignancies.

## **ACHIEVEMENT AND PERFORMANCE**

### **Charitable activities**

The Trustees are committed to the running of the CIO with extremely low overhead costs. The charity does not employ expensive fundraisers but instead relies on voluntary and community efforts to raise funds. The Trustees continue to improve and refine, where necessary, good governance practices without adding an unnecessary burden to operating costs. The trustees remain confident that income streams will increase and will make particular use of social networking and internet-based technologies to achieve this.

The Trustees continue to maintain robust and reliable financial management systems that adhere to current regulations which have proven successful in the past. The Leukaemia Busters CIO has a clear sense of both purpose and direction that is driven by positive outcomes in the research it funds that is viewed as an important incremental step towards clinical benefits for patients. The Leukaemia Busters CIO retains a small but strong group of dedicated Trustees who between them share a good range of skills including scientific, business and management. As a charity funding medical research with responsibility for on-going laboratory and staffing costs we have an obligation to remain financially sound and prudent. Our management systems are transparent and Trustees exercise effective controls over money and assets.

We strongly believe that as an established local charity our clearly stated aims, well publicised achievements and prudent financial management have been the hallmarks of our success. The resultant low administrative overheads that we incur will allow us to truthfully tell organisations and individuals that more than ninety-six pence of every pound donated goes directly towards our charitable objectives. Maintaining our low running costs is absolutely essential if we are to project the right ethos to staff, beneficiaries and the wider public.

The Trustees are mindful of the charity's exposure to risk and have put in place checks and balances designed to minimise these. The charity adheres to all aspects of the General Data Protection Regulations (GDPR) and treats all personal data it collects with absolute confidentiality never sharing this with any third party or to be used in ways that might be considered as unethical.

The scientific research objectives of the charity are clearly stated. Laboratory-based research work streams are carefully costed before commencement to ensure that we operate within the bounds of affordability. Increasing efforts will be made to attract funding from other charitable trusts, supportive academic institutions, government or other international sources. The majority of our funding to date has come from charitable trusts, charitable donations from individuals, other charitable organisations or legacies and we will continue to build on these.

Our financial reporting is scrutinised and approved by the Board of Trustees in twice yearly meetings. *Pro bono* support of our financial reporting is openly offered by Alison Powell ACMA, CGMA, CPFA, our independent examiner. The Trustees are enormously grateful to her for her generosity in offering her free services to the charity. The trustees have elected not to invest capital sum of money but to instead keep the charity's cash assets in bank accounts offering the highest current rate of interest. Bank interest rates are regularly monitored and capital money move as judged appropriate.

The past and present professional contributions to the charity's fully qualified postgraduate and postdoctoral scientific research staff cannot be understated and have been absolutely vital to the success of the charity's stated objectives. In the past all contracts of employment and salary scales for the science staff were drawn up to closely parallel those offered to similarly qualified University of Southampton employees. This helps ensure that we remain competitive for and retain high quality research staff. All our scientific staff have been enrolled on a workplace pension scheme run by the government approved "Smart Pension", identified and selected by the Trustees as being best in terms of online operative simplicity and benefits offered to pension holders. Laboratory operating and consumables costs have been scrutinised, reconciled and allocated at each Board of Trustees meeting. Larger items of equipment are purchased using a 'best value' procedure that entails obtaining a minimum of three quotations and selecting that which offers best value for money.

**LEUKAEMIA BUSTERS**  
**REPORT OF THE TRUSTEES**  
**FOR THE YEAR ENDED 31ST MARCH 2024**

---

The charity's Trustees recognise the growing importance of legacies to our funding and see this as a priority for the future financial health of the charity. The Trustees are enormously grateful to those kind individuals who consider leaving the charity a legacy in their will in particular the late Dennis Heath, the late David Cosway, the late Anne Chapple and the late Jean Emily Grant. Indeed the Trustees are very grateful to all those loyal supporters, past and present, who have unstintingly supported the Leukaemia Busters over the past years and hope that they will be able to continue to do so in the future to keep our work alive. It is these individuals who have made possible the lifesaving work we have conducted in the past.

We thank this year's major funding contributors to the charity's income this year, Hampshire Motocross Club, Newship Group Ltd., Secure Construct and John Breeze. We also extend our sincere thanks to 21Six for their invaluable support of the charity's website. Last but not least we would like to thank all the Friends of Leukaemia Busters who as regular donors make an important and reliable contribution to the charity's income. The Trustees are optimistic that improving economic forecasts will ensure that future funding levels will safeguard the charity's work in funding high quality research that leads to the development of new and improved treatments for leukaemia and other blood cancers.

## **FINANCIAL REVIEW**

### **Investment policy and objectives**

In accordance with the CIO constitution the Trustees have the power to invest in any investments as they see fit to further the objectives of the CIO. The current policy is to adopt a low risk investment strategy based on maximising income from bank deposits.

### **Financial position**

During the year ended 31 March 2024 the CIO received donations and legacies totalling £150,666. The total fund balance at the end of the year amounted to £466,751.

The Trustees confirm that the CIO's assets are available and adequate to fulfil its obligations to meet all existing commitments.

### **Reserves Policy**

The Trustees adopt a reserves policy of maintaining sufficient funds to meet the costs of approved research projects, and to build funds to support work in the future. To ensure that this obligation is fulfilled the trustees have set £100,000, sufficient for one year's worth of laboratory operations as its minimum reserve. The charity nevertheless seeks to establish break clauses in its grant approvals as a matter of prudence to ensure that the charity never becomes overextended.

## **STRUCTURE, GOVERNANCE AND MANAGEMENT**

### **Governing document**

The charity is controlled by its governing document (a constitution) that constitutes a charitable incorporated organisation (CIO).

### **Governance position**

The trustees continue to retain and improve, where necessary, good governance practices without adding an unnecessary burden to operating costs.

### **Recruitment and appointment of new trustees**

All trustees undergo a common selection and induction process. The trustees have highlighted key areas of experience and competency that the trustee group needs to contain. To function effectively the board needs to have diverse skills covering: Business & Governance; Marketing & Media; Scientific & Medical. All new recruited trustees undergo the same application, selection and induction process, to make sure all are fit for purpose, and can make a positive contribution to the charity.

### **Organisational structure**

The board of four trustees provide the steerage and financial control of the charity with the day to day management delegated to the Charity & Scientific Director Dr D J Flavell. Executive Scientific Director Dr S U Flavell together with Dr D J Flavell is responsible for the effective management of the science programmes of the charity through a combination of administrative and scientific skills. A well developed and clearly defined reporting system for the scientific directors to the Trustees has been developed over the years to protect all aspects the charity's position and ensure good governance and best practice. The trustees have set objectives to continue to improve systems and processes in line with market best practice, and the board has formally adopted the "Code of Good Governance" principles.

**LEUKAEMIA BUSTERS**  
**REPORT OF THE TRUSTEES**  
**FOR THE YEAR ENDED 31ST MARCH 2024**

---

**STRUCTURE, GOVERNANCE AND MANAGEMENT**

**Induction and training of new trustees**

All potential new trustees are required to complete a standard application form detailing their skills and the benefits they will bring to the charity. All trustees are provided with the CIO governing document, a role description detailing their responsibilities, and Charity Commission and "Code of Good Governance" good practice guidelines. All appointees are invited to visit the charity's locations and meet with key staff and trustees prior to their application being formally considered by the board. The trustees are kept abreast of regulatory and general governance developments through internal communications, board presentations and other reference material.

**REFERENCE AND ADMINISTRATIVE DETAILS**

**Registered Charity number**

1157147

**Principal address**

c/o Southampton General Hospital  
Mailpoint 3  
Tremona Road  
Southampton  
Hampshire  
SO16 6YD

**Trustees**

R W Sutcliffe  
Dr S U Flavell  
Dr D J Flavell  
Mrs J Sherborne  
Mrs B Robinson-Grindey Resigned date 23/03/2023

**Independent Examiner**

Alison Powell B.Sc. (Hons), ACMA, CGMA, CPFA

**Bankers**

HSBC Bank PLC  
55 Above Bar Street  
Southampton  
SO14 7DZ

Nat West Bank PLC  
12 High Street  
Southampton  
SO14 2BF

Virgin Money  
10 College Place  
Southampton  
Hampshire  
SO15 6YD

**LEUKAEMIA BUSTERS**  
**REPORT OF THE TRUSTEES**  
**FOR THE YEAR ENDED 31ST MARCH 2024**

---

**REFERENCE AND ADMINISTRATIVE DETAILS**

**Patrons**

David and Thorunn Gower

**Officers**

Dr D J Flavell (Charity & Scientific Director)

Dr S U Flavell (Executive Scientific Director)

**Fundraising Presidents**

Harry and Sandra Redknapp

**Ambassadors**

Stewart Dunn

Lawrie McMenemy

Bruce Parker

Sally Taylor

Approved by order of the board of trustees on 31st July 2024 and signed on its behalf by:



.....  
R W Sutcliffe – Chairman of Trustees

**INDEPENDENT EXAMINER'S REPORT TO THE TRUSTEES OF  
LEUKAEMIA BUSTERS**

---

**Independent examiner's report to the trustees of Leukaemia Busters**

I report to the charity trustees on my examination of the accounts of Leukaemia Busters (the CIO) for the year ended 31st March 2024.

**Responsibilities and basis of report**

As the charity trustees of the CIO you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011 ('the Act').


I report in respect of my examination of the CIO's accounts carried out under section 145 of the Act and in carrying out my examination I have followed all applicable Directions given by the Charity Commission under section 145(5)(b) of the Act.

**Independent examiner's statement**

I have completed my examination. I confirm that no material matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

1. accounting records were not kept in respect of the CIO as required by section 130 of the Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.



Alison Powell ACMA, CGMA, CPFA

Date: 31<sup>st</sup> July 2024



# LEUKAEMIA BUSTERS

## STATEMENT OF FINANCIAL ACTIVITIES FOR THE YEAR ENDED 31ST MARCH 2024

	Notes	Unrestricted fund £	Restricted fund £	2024 Total funds £	2023 Total funds £
<b>INCOME FROM</b>					
Donations and legacies	2	123,067	-	123,067	88,849
Fundraising	3	27,600	-	27,600	11,712
Grants		-	-	-	-
Bank Interest	4	10,486	-	10,486	2,448
<b>Total</b>		<b>161,153</b>	<b>-</b>	<b>161,153</b>	<b>103,009</b>
<b>EXPENDITURE ON</b>					
Office and Administration		2,691	-	2,691	3,172
Fundraising Costs		41	-	41	224
Leukaemia research		110,138	-	110,138	105,208
<b>Total</b>		<b>112,870</b>	<b>-</b>	<b>112,870</b>	<b>108,604</b>
<b>NET INCOME/(EXPENDITURE)</b>		<b>48,283</b>	<b>-</b>	<b>48,283</b>	<b>(5,595)</b>
<b>Transfers between funds</b>		<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>Net movement in funds</b>		<b>48,283</b>	<b>-</b>	<b>48,283</b>	<b>(5,595)</b>
<b>RECONCILIATION OF FUNDS</b>					
<b>Total funds brought forward</b>		<b>418,469</b>	<b>-</b>	<b>418,469</b>	<b>424,064</b>
<b>TOTAL FUNDS CARRIED FORWARD</b>		<b>466,752</b>	<b>-</b>	<b>466,752</b>	<b>418,469</b>

The notes form part of these financial statements

**LEUKAEMIA BUSTERS  
BALANCE SHEET  
31ST MARCH 2024**

		Unrestricted fund	Restricted fund	2024 Total funds	2023 Total funds
	Notes	£	£	£	£
<b>FIXED ASSETS</b>					
Tangible assets	9	1,292	-	1,292	1,962
<b>CURRENT ASSETS</b>					
Debtors		-	-	-	-
Cash in hand		467,930	-	467,930	419,618
		467,930	-	467,930	419,618
<b>CREDITORS</b>					
Amounts falling due within one year	10	(2,470)	-	(2,470)	(3,111)
<b>NET CURRENT ASSETS</b>		465,460	-	465,460	416,507
<b>TOTAL ASSETS LESS CURRENT LIABILITIES</b>		466,752	-	466,752	418,469
<b>NET ASSETS</b>		466,752	-	466,752	418,469
<b>FUNDS</b>	11				
Unrestricted funds				466,752	418,469
Restricted funds				-	-
<b>TOTAL FUNDS CARRIED FORWARD</b>				466,752	418,469

The financial statements were approved by the Board of Trustees and authorised for issue on 31<sup>st</sup> July 2024 and were signed on its behalf by:



.....  
R W Sutcliffe – Trustee



.....  
S U Flavell - Trustee

The notes form part of these financial statements

## LEUKAEMIA BUSTERS

### NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH 2024

---

#### 1. ACCOUNTING POLICIES

##### **Basis of preparing the financial statements**

The financial statements of the charity, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2015)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Charities Act 2011. The financial statements have been prepared under the historical cost convention.

##### **Income**

All income is recognised in the Statement of Financial Activities once the charity has entitlement to the funds, it is probable that the income will be received and the amount can be measured reliably.

##### **Expenditure**

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources.

##### **Raising funds**

###### **Fund raising costs**

Fund raising costs represent promotional expenses incurred by the CIO.

###### **Promotional items**

Promotional items are written off in the year of purchase

##### **Tangible fixed assets**

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Plant and machinery                      -    25% on cost

##### **Taxation**

The charity is exempt from tax on its charitable activities.

##### **Fund accounting**

Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees.

Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.

##### **Pension costs and other post-retirement benefits**

The charity operates a defined contribution pension scheme. Contributions payable to the charity's pension scheme are charged to the Statement of Financial Activities in the period to which they relate.

##### **Bank Interest**

Bank Interest is accounted for at the time it is crystallised on the bank statement.

# LEUKAEMIA BUSTERS

## NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 31ST MARCH 2024

### 2. DONATIONS AND LEGACIES

	2024 £	2023 £
Friendship scheme	7,988	8,748
In memoriam/bequests	7,463	4,144
Donations	29,116	16,950
Legacy income	78,500	59,007
Total	123,067	88,849

#### Summary of legacy income

	2024 £	2023 £
The late Paul Vincent Cousins	-	9,816
The late Dorothy Isabel Dewhurst	-	49,191
The late Dennis Heath	5,000	-
The late David Cosway	2,500	-
The late Anne Chapple	1,000	-
The late Jean Emily Grant	70,000	-
	78,500	59,007

### 3. OTHER TRADING ACTIVITIES

	2024 £	2023 £
RideLondon-Essex 100 2022	-	3,831
Gary Meech Coast to Coast walk	-	2,701
Jane Cross Nature Walk, IOW	-	2,481
Len & Jessi 50 <sup>th</sup> Wedding Anniversary	-	1,487
Skydive	-	200
Hampshire Motocross Club 2023	25,042	-
Robert Meech London Marathon 2023	1,329	-
RJ Williams Memorial Golf day	1,103	1,000
Scafell Pike walk	126	12
Total	27,600	11,712

### 4. INVESTMENT INCOME

	2024 £	2023 £
Deposit account interest	10,486	2,448

# LEUKAEMIA BUSTERS

## NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 31ST MARCH 2024

### 5. TRUSTEES' REMUNERATION AND BENEFITS

Two trustees were employed by the charity to manage its scientific research programme for the period ended 31<sup>st</sup> March 2024.

#### Trustees' expenses

There were no trustees' expenses paid for the year ended 31st March 2024 nor for the year ended 31st March 2023.

### 6. STAFF COSTS

The average monthly number of employees during the year was as follows:

	<b>2024</b>	<b>2023</b>
	<b><u>4</u></b>	<b><u>4</u></b>
Scientific staff		

No employees received emoluments in excess of £60,000.

### 7. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES

	Unrestricted fund £	Restricted fund £	Total funds £
<b>INCOME AND ENDOWMENTS FROM</b>			
Donations and legacies	88,849	-	88,849
Other trading activities	11,712	-	11,712
Grant income	-	-	-
Investment income	2,448	-	2,448
<b>Total</b>	<b>103,009</b>	<b>-</b>	<b>103,009</b>
<b>EXPENDITURE ON</b>			
Raising funds	3,396	-	3,396
<b>Charitable activities</b>			
Leukaemia research	105,208	-	105,208
<b>Total</b>	<b>108,604</b>	<b>-</b>	<b>108,604</b>
<b>NET INCOME/(EXPENDITURE)</b>	<b>(5,595)</b>	<b>-</b>	<b>(5,595)</b>
<b>Transfers between funds</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>Net movement in funds</b>	<b>(5,595)</b>	<b>-</b>	<b>(5,595)</b>
<b>RECONCILIATION OF FUNDS</b>			
<b>Total funds brought forward</b>	<b>424,064</b>	<b>-</b>	<b>424,064</b>
<b>TOTAL FUNDS CARRIED FORWARD</b>	<b>418,469</b>	<b>-</b>	<b>418,469</b>

## LEUKAEMIA BUSTERS

### NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 31ST MARCH 2024

---

#### 8. RESTRICTED FUND

The restricted fund includes the following:

Fixed assets

These have been written down in line with the accounting policy.

#### 9. TANGIBLE FIXED ASSETS

	Plant and machinery £
<b>COST</b>	
At 1st April 2023	43,011
Additions	0
At 31st March 2024	<u>43,011</u>
<b>DEPRECIATION</b>	
At 1st April 2023	41,049
Charge for year	670
At 31st March 2024	<u>41,719</u>
<b>NET BOOK VALUE</b>	
At 31st March 2024	<u>1,292</u>
At 31st March 2023	<u>1,962</u>

**LEUKAEMIA BUSTERS**

**NOTES TO THE FINANCIAL STATEMENTS - continued  
FOR THE YEAR ENDED 31ST MARCH 2024**

**10. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR**

	<b>2024</b>	2023
	<b>£</b>	£
Trade creditors	<b>50</b>	115
Taxation and social security	<b>1,727</b>	1,982
Other creditors	<b><u>693</u></b>	<u>1,014</u>
	<b><u>2,470</u></b>	<u>3,111</u>

**11. MOVEMENT IN FUNDS**

	At 01/04/23 £	Net movement in funds £	Transfers between funds £	At 31/03/24 £
<b>Unrestricted funds</b>				
General fund	418,469	<b>48,283</b>	-	<b>466,752</b>
<b>Restricted funds</b>				
Restricted fund	-	-	-	-
	<u>418,469</u>	<u>48,283</u>	<u>-</u>	<u>466,752</u>
<b>TOTAL FUNDS</b>				
	<u>418,469</u>	<u>48,283</u>	<u>-</u>	<u>466,752</u>

Net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
<b>Unrestricted funds</b>			
General fund	<b>161,153</b>	<b>112,870</b>	<b>48,283</b>
<b>Restricted funds</b>			
Restricted fund	-	-	-
	<u>161,153</u>	<u>112,870</u>	<u>48,283</u>
<b>TOTAL FUNDS</b>			
	<u>161,153</u>	<u>112,870</u>	<u>48,283</u>

**Comparatives for movement in funds**

	At 01/04/22 £	Net movement in funds £	Transfers between funds £	At 31/03/23 £
<b>Unrestricted funds</b>				
General fund	424,064	(5,595)	-	418,469
<b>Restricted funds</b>				
Restricted fund	-	-	-	-
	<u>424,064</u>	<u>(5,595)</u>	<u>-</u>	<u>418,469</u>
<b>TOTAL FUNDS</b>				
	<u>424,064</u>	<u>(5,595)</u>	<u>-</u>	<u>418,469</u>

# LEUKAEMIA BUSTERS

## NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 31ST MARCH 2024

### 11. MOVEMENT IN FUNDS – continued

Comparative net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement In funds £
<b>Unrestricted funds</b>			
General fund	103,009	(108,604)	(5,595)
<b>Restricted funds</b>			
Restricted fund	-	-	-
	<hr/>	<hr/>	<hr/>
<b>TOTAL FUNDS</b>	<u>103,009</u>	<u>(108,604)</u>	<u>(5,595)</u>

### 12. RELATED PARTY DISCLOSURES

There were no related transactions for the year ended 31<sup>st</sup> March 2024.